Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with osteoporosis. Zoledronic acid is effective for reducing hip fracture risk among postmenopausal women with ...

Please provide your email address to receive an email when new articles are posted on . Published results showed integration of fracture liaison and orthopedic services, as well as inpatient ...

Zoledronic acid and denosumab demonstrated comparable fracture and mortality outcomes among patients with type 2 diabetes and osteoporosis. Zoledronic acid and denosumab demonstrate comparable ...

ByMiller PD, Pannacciulli N, Brown JP, et al. Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab. 2016, 101(8) ...

Zoledronic acid reduced fracture risk by 27% in men with metastatic prostate cancer receiving ADT in the STAMPEDE trial. Patients with non-metastatic disease showed no significant fracture benefit ...

Zoledronic acid is a bisphosphonate that is being developed for prevention and treatment of osteoporosis. This drug is not approved for treatment or prevention of osteoporosis. Phase 3 testing is ...

Long-term osteoporosis medications are associated with a reduced mortality risk following a fracture, new data suggest. "Treatment for osteoporosis has the potential to minimize mortality risk in ...

Reclast (zoledronic acid or zoledronate) is approved by the Food and Drug Administration (FDA) to treat and prevent osteoporosis in males, females after menopause, and people taking glucocorticoids.

My wife was recently diagnosed with spinal osteoporosis, and her doctor suggested a yearly shot of zoledronic acid. Her insurance already approved it. She is checking the side effects, which showed a ...